Literature DB >> 24080801

Vasculitis syndromes: RAVE about rituximab in ANCA vasculitis?

Ruth Tarzi1, Charles Pusey.   

Abstract

Follow-up data from the RAVE trial have shown that rituximab is as effective as immunosuppression with cyclophosphamide followed by azathioprine in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis. Rituximab is likely to become the standard of care for many patients with ANCA disease. However, an individualized approach is needed to identify those who require more-intense or prolonged therapy.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24080801     DOI： 10.1038/nrneph.2013.204

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  10 in total

1.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Rona M Smith; Rachel B Jones; Mary-Jane Guerry; Simona Laurino; Fausta Catapano; Afzal Chaudhry; Kenneth G C Smith; David R W Jayne
Journal:  Arthritis Rheum       Date:  2012-11

Review 4.  Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials.

Authors:  C Heijl; L Harper; O Flossmann; I Stücker; D G I Scott; R A Watts; P Höglund; K Westman; A Mahr
Journal:  Ann Rheum Dis       Date:  2011-05-25       Impact factor: 19.103

5.  Wegener's granulomatosis: studies in eighteen patients and a review of the literature.

Authors:  A S Fauci; S M Wolff
Journal:  Medicine (Baltimore)       Date:  1973-11       Impact factor: 1.889

6.  Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis.

Authors:  Nicholas Mansfield; Sally Hamour; Anne-Marie Habib; Ruth Tarzi; Jeremy Levy; Megan Griffith; Tom Cairns; H Terence Cook; Charles D Pusey; Alan D Salama
Journal:  Nephrol Dial Transplant       Date:  2011-03-17       Impact factor: 5.992

7.  Efficacy of remission-induction regimens for ANCA-associated vasculitis.

Authors:  Ulrich Specks; Peter A Merkel; Philip Seo; Robert Spiera; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Barri J Fessler; Linna Ding; Lisa Viviano; Nadia K Tchao; Deborah J Phippard; Adam L Asare; Noha Lim; David Ikle; Brett Jepson; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Mark Mueller; Lourdes P Sejismundo; Kathleen Mieras; John H Stone
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

Review 8.  Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production.

Authors:  J Voswinkel; A Müller; P Lamprecht
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

9.  Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

Authors:  Kirsten de Groot; Lorraine Harper; David R W Jayne; Luis Felipe Flores Suarez; Gina Gregorini; Wolfgang L Gross; Rashid Luqmani; Charles D Pusey; Niels Rasmussen; Renato A Sinico; Vladimir Tesar; Philippe Vanhille; Kerstin Westman; Caroline O S Savage
Journal:  Ann Intern Med       Date:  2009-05-19       Impact factor: 25.391

10.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245
  10 in total
  1 in total

Review 1.  CD20+ B cell depletion in systemic autoimmune diseases: common mechanism of inhibition or disease-specific effect on humoral immunity?

Authors:  Panagiotis Pateinakis; Athina Pyrpasopoulou
Journal:  Biomed Res Int       Date:  2014-03-27       Impact factor: 3.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.